Previous close | 5.68 |
Open | 5.94 |
Bid | 6.50 |
Ask | 7.00 |
Strike | 25.00 |
Expiry date | 2024-12-20 |
Day's range | 5.59 - 5.94 |
Contract range | N/A |
Volume | |
Open interest | 220 |
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.